Pass Infection Control CIC exam [Apr 14, 2026] Updated 302 Questions
CBIC CIC Actual Questions and 100% Cover Real Exam Questions
NEW QUESTION # 141
A healthy long-term employee with a history of Bacillus Calmette-Guerin (BCG) vaccination has a Tuberculin Skin Test (TST) result of 7 mm induration. The current Centers for Disease Control and Prevention (CDC) recommendations include which of the following?
- A. No further action is required
- B. Refer the employee to a physician for treatment
- C. Repeat the test in 1 to 3 weeks
- D. Send the employee for a chest x-ray
Answer: A
Explanation:
The CBIC Certified Infection Control Exam Study Guide (6th edition) aligns with CDC guidance regarding interpretation of the tuberculin skin test (TST) in healthcare personnel. For a healthy individual with no known risk factors for tuberculosis, a TST is considered positive only when induration is #10 mm. In this scenario, the employee's TST result of 7 mm induration is negative and does not meet the threshold for latent TB infection.
A prior history of BCG vaccination does not change interpretation criteria in adults. The CDC explicitly recommends that TST results be interpreted regardless of BCG history, as vaccine-related reactivity typically wanes over time and induration should not be attributed to BCG alone. Therefore, a 7 mm reaction in a low- risk, asymptomatic healthcare worker does not require further diagnostic evaluation.
Option A (chest x-ray) is reserved for individuals with a positive TB test or symptoms suggestive of active TB. Option C (repeat testing) is not indicated unless this was part of a two-step baseline test and the first result was negative in a newly hired employee, which is not the case here. Option D is inappropriate because treatment is only considered after confirmed latent TB infection.
For the CIC exam, it is essential to recognize that no further action is required when TST induration is below the positive threshold for the individual's risk category, even in those with prior BCG vaccination.
NEW QUESTION # 142
An infection preventionist is utilizing the Shewhart/Deming cycle in an infection control program performance improvement project. In which of the following steps are the results of the interventions compared with the original goal?
- A. Act
- B. Plan
- C. Do
- D. Study
Answer: D
Explanation:
The correct answer is D, "Study," as this is the step in the Shewhart/Deming cycle (commonly known as the Plan-Do-Study-Act [PDSA] cycle) where the results of the interventions are compared with the original goal.
According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, the PDSA cycle is a systematic approach to quality improvement, widely used in infection control programs to test and refine interventions. The cycle consists of four stages: Plan (designing the intervention and setting goals), Do (implementing the intervention on a small scale), Study (analyzing the data and comparing outcomes against the original goal), and Act (standardizing successful changes or adjusting based on findings) (CBIC Practice Analysis, 2022, Domain IV: Education and Research, Competency 4.2 - Evaluate the effectiveness of educational programs). The Study phase is critical for assessing whether the intervention achieved the intended reduction in infection rates or other performance metrics, providing evidence to guide the next steps.
Option A (Do) involves the execution of the planned intervention, focusing on implementation rather than evaluation, so it does not include comparing results. Option B (Act) is the final step where successful interventions are implemented on a broader scale or adjustments are made, but it follows the comparison made in the Study phase. Option C (Plan) is the initial stage of setting objectives and designing the intervention, which occurs before any results are available for comparison.
The emphasis on the Study phase aligns with CBIC's focus on using data to evaluate the effectiveness of infection prevention strategies, ensuring that performance improvement projects are evidence-based and goal- oriented (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.4 - Evaluate the effectiveness of infection prevention and control interventions). This step enables the infection preventionist to determine if the original goal-such as reducing healthcare-associated infections-was met, facilitating continuous improvement.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.4 - Evaluate the effectiveness of infection prevention and control interventions; Domain IV:
Education and Research, Competency 4.2 - Evaluate the effectiveness of educational programs.
NEW QUESTION # 143
The MOST common reason for contamination of compounded pharmaceutical products is:
- A. Inadequate laminar airflow
- B. Infrequent environmental sampling
- C. Direct touch by personnel
- D. Inappropriate storage of pharmaceutical items
Answer: C
Explanation:
The CBIC Certified Infection Control Exam Study Guide (6th edition) identifies direct touch contamination by personnel as the most common cause of contamination of compounded pharmaceutical products. Human contact-particularly hands, gloves, sleeves, or improper manipulation of sterile components-is the greatest source of microbial contamination during compounding activities.
Even when engineering controls such as laminar airflow workbenches and cleanrooms are functioning correctly, contamination can occur if aseptic technique is not strictly followed. Touching sterile vial stoppers, syringe tips, needle hubs, or critical sites with nonsterile hands or gloves introduces microorganisms directly into the product. The Study Guide emphasizes that aseptic technique, hand hygiene, glove use, and competency validation are essential to preventing contamination.
Option B, inadequate laminar airflow, can contribute to contamination but is less common than direct touch errors and is usually detected through certification and monitoring. Option C, infrequent environmental sampling, does not cause contamination but may delay detection of problems. Option D, inappropriate storage, can affect product stability but is not the primary cause of contamination during compounding.
For CIC exam preparation, it is critical to recognize that human factors are the leading source of contamination in sterile compounding. Infection prevention strategies therefore focus heavily on staff training, competency assessment, observation, and adherence to aseptic technique standards to reduce contamination risk.
NEW QUESTION # 144
Which of the following process performance indicators should result in improvement in central line- associated bloodstream infections (CLABSI)?
- A. 100% compliance with the insertion bundle.
- B. Povidone-iodine antiseptic ointment placed at the insertion site of a peripherally inserted central catheter line.
- C. Routinely changing the central line over a guidewire every seven days.
- D. All patients with a central line are on total parenteral nutrition (TPN).
Answer: A
Explanation:
The Certification Study Guide (6th edition) emphasizes that process performance indicators directly linked to evidence-based practices are the most effective measures for reducing healthcare-associated infections such as CLABSI. Among the options listed, 100% compliance with the central line insertion bundle is the only indicator consistently demonstrated to reduce CLABSI rates.
Insertion bundles are standardized sets of practices that include proper hand hygiene, maximal sterile barrier precautions, use of appropriate skin antisepsis (preferably chlorhexidine), optimal catheter site selection, and daily review of line necessity. The study guide explains that reliable execution of these bundled practices addresses the most common routes of microbial entry at the time of line placement, which is a critical risk period for bloodstream infection.
The other options do not represent valid improvement indicators. Total parenteral nutrition is a known risk factor for CLABSI, not a prevention strategy. Use of povidone-iodine ointment at insertion sites is not recommended and may increase infection risk. Routine guidewire exchanges are discouraged because they do not reduce infection risk and may increase contamination.
Therefore, measuring and achieving full compliance with the insertion bundle is a meaningful, actionable performance indicator that aligns with CBIC exam expectations and infection prevention best practices.
Reference: Certification Study Guide (CBIC/CIC Exam Study Guide), 6th edition, Chapter 5: Preventing
/Controlling the Transmission of Infectious Agents; Chapter 4: Surveillance and Epidemiologic Investigation.
\
NEW QUESTION # 145
Which of the following management activities should be performed FIRST?
- A. Assign responsibility for projects
- B. Evaluate project results
- C. Plan and organize activities
- D. Establish goals
Answer: D
Explanation:
To determine which management activity should be performed first, we need to consider the logical sequence of steps in effective project or program management, particularly in the context of infection control as guided by CBIC principles. Management activities typically follow a structured process, and the order of these steps is critical to ensuring successful outcomes.
* A. Evaluate project results: Evaluating project results involves assessing the outcomes and effectiveness of a project after its implementation. This step relies on having completed the project or at least reached a stage where outcomes can be measured. Performing this activity first would be premature, as there would be no results to evaluate without prior planning, goal-setting, and execution. Therefore, this cannot be the first step.
* B. Establish goals: Establishing goals is the foundational step in any management process. Goals provide direction, define the purpose, and set the criteria for success. In the context of infection control, as emphasized by CBIC, setting clear objectives (e.g., reducing healthcare-associated infections by a specific percentage) is essential before any other activities can be planned or executed. This step aligns with the initial phase of strategic planning, making it the logical first activity. Without established goals, subsequent steps lack focus and purpose.
* C. Plan and organize activities: Planning and organizing activities involve developing a roadmap to achieve the goals, including timelines, resources, and tasks. This step depends on having clear goals to guide the planning process. In infection control, this might include designing interventions to meet infection reduction targets. While critical, it cannot be the first step because planning requires a predefined objective to be effective.
* D. Assign responsibility for projects: Assigning responsibility involves delegating tasks and roles to individuals or teams. This step follows the establishment of goals and planning, as responsibilities need to be aligned with the specific objectives and organized activities. In an infection control program, this might mean assigning staff to monitor compliance with hand hygiene protocols. Doing this first would be inefficient without a clear understanding of the goals and plan.
The correct sequence in management, especially in a structured field like infection control, begins with establishing goals to provide a clear target. This is followed by planning and organizing activities, assigning responsibilities, and finally evaluating results. The CBIC framework supports this approach by emphasizing the importance of setting measurable goals as part of the infection prevention and control planning process, which is a prerequisite for all subsequent actions.
References:
* CBIC Infection Prevention and Control (IPC) Core Competency Model (updated 2023), Domain V:
Management and Communication, which highlights the importance of setting goals as the initial step in managing infection control programs.
* CBIC Examination Content Outline, Domain V: Leadership and Program Management, which underscores the need for goal-setting prior to planning and implementation of infection control initiatives.
NEW QUESTION # 146
Which of the following is an example of an outcome measure?
- A. Rate of multi-drug resistant organisms acquisition
- B. Hand hygiene compliance rate
- C. Timing of preoperative antibiotic administration
- D. Adherence to Environmental Cleaning
Answer: A
Explanation:
The correct answer is C, "Rate of multi-drug resistant organisms acquisition," as it represents an example of an outcome measure. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, outcome measures are indicators that reflect the impact or result of infection prevention and control interventions on patient health outcomes or the incidence of healthcare-associated infections (HAIs).
The rate of multi-drug resistant organisms (MDRO) acquisition directly measures the incidence of new infections caused by resistant pathogens, which is a key outcome affected by the effectiveness of infection control practices (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.4 - Evaluate the effectiveness of infection prevention and control interventions).
Option A (hand hygiene compliance rate) is an example of a process measure, which tracks adherence to specific protocols or practices intended to prevent infections, rather than the resulting health outcome. Option B (adherence to environmental cleaning) is also a process measure, focusing on the implementation of cleaning protocols rather than the end result, such as reduced infection rates. Option D (timing of preoperative antibiotic administration) is another process measure, assessing the timeliness of an intervention to prevent surgical site infections, but it does not directly indicate the outcome (e.g., infection rate) of that intervention.
Outcome measures, such as the rate of MDRO acquisition, are critical for evaluating the success of infection prevention programs and are often used to guide quality improvement initiatives. This aligns with CBIC's emphasis on using surveillance data to assess the effectiveness of interventions and inform decision-making (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 - Use data to guide infection prevention and control strategies). The focus on MDRO acquisition specifically highlights a significant healthcare challenge, making it a prioritized outcome measure in infection control.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competencies 2.4 - Evaluate the effectiveness of infection prevention and control interventions, 2.5 - Use data to guide infection prevention and control strategies.
NEW QUESTION # 147
An infection preventionist (IP) is asked to participate on a team to decrease ventilator-associated pneumonia (VAP) rates in a 20-bed ICU. The IP provides the following information. What is the first quarter ventilator utilization ratio?
Data Provided (First Quarter):
* Ventilator days (Jan-Mar total): 800
* Patient days (Jan-Mar total): 1200
- A. 0.67
- B. 0.13
- C. 1.50
- D. 1.67
Answer: A
Explanation:
The Certification Study Guide (6th edition) defines the ventilator utilization ratio (VUR) as a device utilization measure used in surveillance to describe the proportion of patient time during which a specific medical device-in this case, mechanical ventilation-is in use. It is calculated by dividing the total number of ventilator days by the total number of patient days for the same location and time period.
Using the first-quarter data provided, the calculation is as follows:
Ventilator Utilization Ratio = Ventilator Days ÷ Patient Days
Ventilator Utilization Ratio = 800 ÷ 1200 = 0.67
This means that ventilators were in use for 67% of all patient days in the ICU during the first quarter. The study guide emphasizes that device utilization ratios are essential for interpreting device-associated infection data, such as VAP rates, because they reflect the level of patient exposure to the device. Higher utilization increases the population at risk and can influence infection rates independently of prevention practices.
The other answer options are incorrect because they do not reflect the correct calculation. A ratio greater than
1.0 (options C and D) would imply more device days than patient days, which is not possible in this context.
Option A underestimates utilization and does not match the provided data.
Understanding and correctly calculating utilization ratios is a core CIC exam competency, as these metrics support accurate surveillance, benchmarking, and performance improvement efforts.
Reference: Certification Study Guide (CBIC/CIC Exam Study Guide), 6th edition, Chapter 4: Surveillance and Epidemiologic Investigation.
NEW QUESTION # 148
Which of the following is an example of a syndromic surveillance indicator?
- A. Number of cases of methicillin-resistant Staphylococcus aureus in an intensive care unit each month
- B. Number of individuals presenting with laboratory-confirmed influenza in the emergency department each day
- C. Number of individuals presenting with influenza-like illness in the emergency department each day
- D. Rate of central line-associated bloodstream infections each quarter
Answer: C
Explanation:
The CBIC Certified Infection Control Exam Study Guide (6th edition) describes syndromic surveillance as a surveillance method that focuses on clinical signs, symptoms, or health-seeking behaviors rather than confirmed diagnoses. Its primary purpose is early detection of outbreaks or emerging health threats, often before laboratory confirmation is available.
Option A is the correct example because tracking the number of individuals presenting with influenza-like illness (ILI) relies on symptom patterns such as fever, cough, and sore throat. These data are typically collected in near real time from emergency department chief complaints or triage notes, allowing infection preventionists and public health authorities to identify unusual increases quickly and initiate early response measures.
Option B is not syndromic surveillance because it depends on laboratory-confirmed diagnoses, which are characteristic of traditional, diagnosis-based surveillance. Option C represents device-associated infection surveillance, which is retrospective and outcome-focused. Option D involves laboratory-confirmed antimicrobial-resistant organisms and is also not syndromic.
For CIC exam preparation, it is important to remember that syndromic surveillance prioritizes speed over diagnostic certainty. By monitoring symptom clusters rather than confirmed cases, it enables earlier recognition of outbreaks such as influenza, gastrointestinal illness, or bioterrorism-related events, making it a critical component of public health preparedness and response.
NEW QUESTION # 149
A surgical team is performing a liver transplant. Which of the following represents the HIGHEST risk for transmission of a healthcare-associated infection?
- A. Using alcohol-based hand rub instead of surgical scrub.
- B. Delayed administration of preoperative antibiotics.
- C. Failure to change surgical gloves after contamination.
- D. Airflow disruption due to personnel movement.
Answer: C
Explanation:
* Glove Contamination and SSI Risk:
* Failure to change contaminated gloves increases the risk of surgical site infections (SSIs).
* Double-gloving with an outer glove change reduces contamination.
* Why Other Options Are Incorrect:
* B. Alcohol-based hand rubs: Are FDA-approved alternatives to traditional scrubs and effective.
* C. Delayed antibiotics: Increases infection risk, but immediate correction reduces harm.
* D. Airflow disruption: Can increase SSI risk, but glove contamination poses a more direct threat.
CBIC Infection Control References:
* APIC-JCR Workbook, "Surgical Infection Prevention," Chapter 6.
NEW QUESTION # 150
Which water type is suitable for drinking yet may still be a risk for disease transmission?
- A. Potable water
- B. Purified water
- C. Grey water
- D. Distilled water
Answer: A
Explanation:
To determine which water type is suitable for drinking yet may still pose a risk for disease transmission, we need to evaluate each option based on its definition, treatment process, and potential for contamination, aligning with infection control principles as outlined by the Certification Board of Infection Control and Epidemiology (CBIC).
* A. Purified water: Purified water undergoes a rigorous treatment process (e.g., reverse osmosis, distillation, or deionization) to remove impurities, contaminants, and microorganisms. This results in water that is generally safe for drinking and has a very low risk of disease transmission when properly handled and stored. However, if the purification process is compromised or if contamination occurs post-purification (e.g., due to improper storage or distribution), there could be a theoretical risk.
Nonetheless, purified water is not typically considered a primary source of disease transmission under standard conditions.
* B. Grey water: Grey water refers to wastewater generated from domestic activities such as washing dishes, laundry, or bathing, which may contain soap, food particles, and small amounts of organic matter. It is not suitable for drinking due to its potential contaminationwith pathogens (e.g., bacteria, viruses) and chemicals. Grey water is explicitly excluded from potable water standards and poses a significant risk for disease transmission, making it an unsuitable choice for this question.
* C. Potable water: Potable water is water that meets regulatory standards for human consumption, as defined by organizations like the World Health Organization (WHO) or the U.S. Environmental Protection Agency (EPA). It is treated to remove harmful pathogens and contaminants, making it safe for drinking under normal circumstances. However, despite treatment, potable water can still pose a risk for disease transmission if the distribution system is contaminated (e.g., through biofilms, cross- connections, or inadequate maintenance of pipes). Outbreaks of waterborne diseases like Legionnaires' disease or gastrointestinal infections have been linked to potable water systems, especially in healthcare settings. This makes potable water the best answer, as it is suitable for drinking yet can still carry a risk under certain conditions.
* D. Distilled water: Distilled water is produced by boiling water and condensing the steam, which removes most impurities, minerals, and microorganisms. It is highly pure and safe for drinking, often used in medical and laboratory settings. Similar to purified water, the risk of disease transmission is extremely low unless contamination occurs after distillation due to improper handling or storage. Like purified water, it is not typically associated with disease transmission risks in standard use.
The key to this question lies in identifying a water type that is both suitable for drinking and has a documented potential for disease transmission. Potable water fits this criterion because, while it is intended for consumption and meets safety standards, it can still be a vector for disease if the water supply or distribution system is compromised. This is particularly relevant in infection control, where maintaining water safety in healthcare facilities is a critical concern addressed by CBIC guidelines.
:
CBIC Infection Prevention and Control (IPC) Core Competency Model (updated 2023), Domain III:
Prevention and Control of Infectious Diseases, which highlights the importance of water safety and the risks of contamination in potable water systems.
CBIC Examination Content Outline, Domain IV: Environment of Care, which includes managing waterborne pathogens (e.g., Legionella) in potable water supplies.
NEW QUESTION # 151
Which of the following is an essential element of practice when sending biohazardous samples from one location to another?
- A. Ship using triple-containment packaging
- B. Electronically log and send via overnight delivery
- C. Store in a cooler that is labeled as a health hazard
- D. Transport by an authorized biohazard transporter
Answer: A
Explanation:
The safe transport of biohazardous samples, such as infectious agents, clinical specimens, or diagnostic materials, is a critical aspect of infection prevention and control to prevent exposure and environmental contamination. The Certification Board of Infection Control and Epidemiology (CBIC) emphasizes adherence to regulatory and safety standards in the "Prevention and Control of Infectious Diseases" domain, which includes proper handling and shipping of biohazardous materials. The primary guideline governing this practice is the U.S. Department of Transportation (DOT) Hazardous Materials Regulations (HMR) and the International Air Transport Association (IATA) Dangerous Goods Regulations, which align with global biosafety standards.
Option A, "Ship using triple-containment packaging," is the essential element of practice. Triple-containment packaging involves three layers: a primary watertight container holding the sample, a secondary leak-proof container with absorbent material, and an outer rigid packaging (e.g., a box) that meets shipping regulations.
This system ensures that biohazardous materials remain secure during transport, preventing leaks or breaches that could expose handlers or the public. The CDC and WHO endorse this method as a fundamental requirement for shipping Category A (high-risk) and Category B (moderate-risk) infectious substances, making it the cornerstone of safe transport practice.
Option B, "Electronically log and send via overnight delivery," is a useful administrative and logistical step to track shipments and ensure timely delivery, but it is not the essential element. While documentation and rapid delivery are important for maintaining chain of custody and sample integrity, they are secondary to the physical containment provided by triple packaging. Option C, "Transport by an authorized biohazard transporter," is a necessary step to comply with regulations, as only trained and certified transporters can handle biohazardous materials. However, this is contingent on proper packaging; without triple containment, transport authorization alone is insufficient. Option D, "Store in a cooler that is labeled as a health hazard," may be part of preparation (e.g., maintaining sample temperature), but labeling alone does not address the containment or transport safety required during shipment. Coolers are often used, but the focus on labeling as a health hazard is incomplete without the triple-containment structure.
The CBIC Practice Analysis (2022) supports compliance with federal and international shipping regulations, which prioritize triple-containment packaging as the foundational practice to mitigate risks. The CDC's Biosafety in Microbiological and Biomedical Laboratories (BMBL, 6th Edition, 2020) and IATA guidelines further specify that triple packaging is mandatory for all biohazardous shipments, reinforcing Option A as the correct answer.
References:
* CBIC Practice Analysis, 2022.
* CDC Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition, 2020.
* U.S. DOT Hazardous Materials Regulations (49 CFR Parts 171-180).
* IATA Dangerous Goods Regulations, 2023.
NEW QUESTION # 152
One of the elements of antibiotic stewardship is controlling antibiotic use. Which of the following BEST describes a closed formulary?
- A. Limits the number of antibiotics available for physicians to prescribe.
- B. Practice of rotating two or more classes of formulary drugs on a regular basis.
- C. Automatic switching from broad-spectrum empiric therapy to narrower-spectrum agents.
- D. Requires the prescribing physician to obtain some form of approval before the antibiotic will be dispensed.
Answer: D
Explanation:
Antibiotic stewardship programs are designed to optimize antimicrobial use, improve patient outcomes, reduce antimicrobial resistance, and decrease unnecessary costs. The CBIC Certified Infection Control Exam Study Guide (6th edition) identifies formulary restriction and preauthorization as key core strategies within effective antimicrobial stewardship programs. A closed formulary specifically refers to a system in which access to certain antibiotics is restricted and requires prior approval before dispensing.
In a closed formulary model, prescribers must obtain authorization-often from infectious diseases specialists, pharmacy, or an antimicrobial stewardship team-before selected antimicrobial agents can be used. This approach ensures that high-risk, broad-spectrum, or high-cost antibiotics are used only when clinically appropriate. By requiring approval, the organization promotes judicious antibiotic selection, prevents unnecessary exposure, and supports resistance prevention efforts.
Option B describes de-escalation, which is another stewardship strategy but does not define a closed formulary. Option C refers to antibiotic cycling, a controversial and less-supported strategy. Option D is incorrect because a closed formulary does not merely limit availability; rather, it controls access through approval mechanisms.
For the CIC exam, it is critical to distinguish between stewardship strategies. A closed formulary is best characterized by mandatory approval prior to dispensing, making option A the most accurate answer according to the Study Guide's antimicrobial stewardship framework.
NEW QUESTION # 153
The effectiveness of disinfection is NOT dependent upon the:
- A. Length of exposure to the chemical agent
- B. Virulence of the organism
- C. Spore-forming ability of the organism
- D. Amount of organic material present
Answer: B
Explanation:
The CBIC Certified Infection Control Exam Study Guide (6th edition) explains that the effectiveness of disinfection depends on multiple physical, chemical, and biologic factors, but virulence of the organism is not one of them. Virulence refers to an organism's ability to cause disease in a host, which is a clinical characteristic, not a determinant of susceptibility to disinfectants.
Disinfection efficacy is influenced by factors such as the type and number of microorganisms, particularly their intrinsic resistance (for example, spores are more resistant than vegetative bacteria), making option C a true determinant. The amount of organic material present (option B) is also critical, as organic matter can inactivate disinfectants or shield microorganisms from exposure. Likewise, the length of exposure (contact time) to the chemical agent (option D) is essential to achieving the desired level of microbial kill and is specified in manufacturer instructions for use.
Virulence does not affect how easily an organism is destroyed by a disinfectant. For example, a highly virulent organism may be easily killed by a low-level disinfectant, while a less virulent organism such as a bacterial spore may be highly resistant. Therefore, virulence plays no role in determining disinfection effectiveness.
For CIC exam preparation, it is important to distinguish between clinical severity and microbial resistance.
Disinfection effectiveness is based on resistance characteristics and process variables-not on how dangerous the organism is to humans.
NEW QUESTION # 154
The infection preventionist (IP) is assisting pharmacists in investigating medication contamination at the hospital's compounding pharmacy. As part of the medication recall process, the IP should:
- A. Have laboratory culture all medication.
- B. Inform all discharged patients of potential medication contamination.
- C. Identify the potential source of contamination.
- D. Inspect for safe injection practices.
Answer: C
Explanation:
The scenario involves an infection preventionist (IP) assisting pharmacists in addressing medication contamination at the hospital's compounding pharmacy, with a focus on the medication recall process. The IP' s role is to apply infection control expertise to mitigate risks, guided by the Certification Board of Infection Control and Epidemiology (CBIC) principles and best practices. The recall process requires a systematic approach to identify, contain, and resolve the issue, and the "first" or most critical step must be determined.
Let's evaluate each option:
* A. Have laboratory culture all medication: Culturing all medication to confirm contamination is a valuable step to identify affected batches and guide the recall. However, this is a resource-intensive process that depends on first understanding the scope and source of the problem. Without identifying the potential source of contamination, culturing all medication could be inefficient and delay the recall.
This step is important but secondary to initial investigation.
* B. Inspect for safe injection practices: Inspecting for safe injection practices (e.g., single-use vials, proper hand hygiene, sterile technique) is a critical infection control measure, especially in compounding pharmacies where contamination often arises from procedural errors (e.g., reuse of syringes, improper cleaning). While this is a proactive step to prevent future contamination, it addresses ongoing practices rather than the immediate recall process for the current contamination event. It is a complementary action but not the first priority.
* C. Identify the potential source of contamination: Identifying the potential source of contamination is the foundational step in the recall process. This involves investigating the compounding environment (e.
g., water quality, equipment, personnel practices), raw materials, and production processes to pinpoint where the contamination occurred (e.g., bacterial ingress, cross-contamination). The CBIC emphasizes root cause analysis as a key infection prevention strategy, enabling targeted recalls, corrective actions, and prevention of recurrence. This step is essential before culturing, inspecting, or notifying patients, making it the IP's primary responsibility in this context.
* D. Inform all discharged patients of potential medication contamination: Notifying patients is a critical step to ensure public safety and allow for medical follow-up if they received contaminated medication.
However, this action requires prior identification of the contaminated batches and their distribution, which depends on determining the source and confirming the extent of the issue. Premature notification without evidence could cause unnecessary alarm and is not the first step in the recall process.
The best answer is C, as identifying the potential source of contamination is the initial and most critical step in the medication recall process. This allows the IP to collaborate with pharmacists to trace the contamination, define the affected products, and guide subsequent actions (e.g., culturing, inspections, notifications). This aligns with CBIC's focus on systematic investigation and risk mitigation in healthcare-associated infection events.
References:
* CBIC Infection Prevention and Control (IPC) Core Competency Model (updated 2023), Domain III:
Prevention and Control of Infectious Diseases, which includes identifying sources of contamination in healthcare settings.
* CBIC Examination Content Outline, Domain V: Management and Communication, which emphasizes root cause analysis during outbreak investigations.
* CDC Guidelines for Safe Medication Compounding (2022), which recommend identifying contamination sources as the first step in a recall process.
NEW QUESTION # 155
A healthcare worker experiences a percutaneous exposure to a patient with untreated HIV. The next step is to:
- A. Offer post-exposure prophylaxis only if symptoms develop.
- B. Wait for HIV test results before starting treatment.
- C. Retest for HIV after 6 months before deciding on PEP.
- D. Initiate HIV post-exposure prophylaxis (PEP) within 2 hours.
Answer: D
Explanation:
* HIV post-exposure prophylaxis (PEP) should be initiated within 2 hours to be most effective.
* Waiting for results (B) delays critical treatment.
* PEP should always be offered after high-risk exposure, not only if symptoms develop (C).
* Retesting after 6 months (D) is recommended but should not delay PEP initiation.
CBIC Infection Control References:
* APIC Text, "Bloodborne Pathogens and PEP," Chapter 11.
NEW QUESTION # 156
......
CBIC CIC Real 2026 Braindumps Mock Exam Dumps: https://pass4sure.test4cram.com/CIC_real-exam-dumps.html